EVALUATION OF CHIP (IPROPLATIN) IN RECURRENT PEDIATRIC MALIGNANT SOLID TUMORS - A PHASE-II STUDY (PEDIATRIC ONCOLOGY GROUP)

R NITSCHKE, C PRATT, M HARRIS, J KRISCHER, TJ VIETTI, H GRIER, W KAMPS, S TOLEDANO

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

CHIP (325 mg/M2), a second generation cisplatin derivative, was administered intravenously every 3 weeks to 85 pediatric patients with recurrent sarcomas (19), osteosarcomas (20), neuroblastoma (23), germ cell tumors (10), and other malignant tumors (7). Thirty-eight of them had been previously exposed to cisplatin.

Partial remissions were only observed in 3 of 23 (13% SE = 7%) patients having neuroblastoma. Severe thrombocytopenia (65%) and neutropenia (35%) were the dose limiting factors.

Original languageEnglish
Pages (from-to)93-96
Number of pages4
JournalInvestigational new drugs
Volume10
Issue number2
Publication statusPublished - Jul-1992

Keywords

  • CHIP
  • PEDIATRIC MALIGNANCIES
  • RECURRENT PEDIATRIC MALIGNANT SOLID TUMORS
  • PHASE-II STUDY

Cite this